For Suruchi Mishra, the Next-Gen Healthcare Leader Award at the ET Healthcare Awards 2026 is less a personal milestone than a reflection of the ecosystem around her. Her journey at GeneBio Healthcare has unfolded across research, product development, regulatory affairs, quality, manufacturing and business growth, giving her a vantage point that extends well beyond any single function.
It has also shaped a distinct view of what leadership in healthcare demands. Innovation, she believes, cannot exist in isolation. A scientific idea acquires significance only when it can navigate the demanding passage from laboratory research to a product that is reliable, compliant and meaningful for patients and healthcare professionals.
That philosophy sits at the heart of her work at GeneBio Healthcare, an organisation engaged in the development, manufacturing and marketing of in-vitro diagnostic kits and reagents, alongside continuous research and product improvement. For Mishra, the larger ambition is to create the conditions in which indigenous innovation can move beyond the research environment and become a practical healthcare intervention.
The need for such a transition is particularly evident in diagnostics, one of the foundational pillars of clinical decision-making. Speed, accuracy, affordability, accessibility and quality must progress in tandem, yet aligning these imperatives remains one of the ecosystem’s persistent challenges. India possesses substantial scientific and technical capability, but the pathway from research to scalable, commercially viable diagnostic solutions can be strengthened further.
GeneBio’s response has been to build an integrated continuum spanning R&D, product development, regulatory compliance, quality systems, manufacturing and market access. Its engagement with research institutions, including the Indian Council of Medical Research (ICMR), forms an important component of this approach. Through technology-transfer and licensing initiatives, GeneBio is working to bring research-led technologies closer to practical diagnostic applications.
For Mishra, however, translating innovation into the market does not mean compromising on rigour. In diagnostics, technological sophistication has limited value if performance cannot be reproduced consistently. This makes quality not a final checkpoint but an intrinsic component of product development.
At GeneBio, R&D works in close alignment with quality, regulatory and manufacturing teams, ensuring that scientific advancement is accompanied by validation, documentation, process controls and regulatory discipline. Manufacturing, meanwhile, is anchored in consistency, traceability, testing and continuous improvement. The objective is to create products that healthcare professionals can rely upon over the long term.
The same thinking informs decisions around GeneBio’s product portfolio. Each development begins with a fundamental question: what healthcare need is being addressed? Scientific potential is then considered alongside clinical relevance, usability, quality requirements, regulatory pathways and manufacturing feasibility. Scalability and accessibility remain equally important considerations.
This approach has encouraged GeneBio to work across diverse areas of infectious disease diagnostics while continuing to explore newer technologies. Research collaborations add another dimension, creating avenues through which promising scientific work can be evaluated for translation into usable diagnostic solutions.
The industry itself is entering a period of considerable technological evolution. Mishra sees molecular diagnostics, multiplex testing, nucleic-acid-based technologies, improved point-of-care platforms and the greater integration of digital technologies as developments likely to shape the coming years. Across these advances, the underlying priorities remain clear: greater speed, sensitivity, decentralisation and a more precise understanding of disease at the molecular level.
Early and accurate detection will be particularly consequential in infectious diseases, where timely diagnosis can influence both treatment decisions and disease-control strategies. GeneBio is strengthening its R&D capabilities, technology-transfer initiatives and institutional collaborations to participate in this transition.
A significant marker of that effort is its association with 20 ICMR-patented products, alongside additional technologies and products progressing through its development and documentation pipeline. For GeneBio, these represent not merely a portfolio of technologies, but an opportunity to build a bridge between scientific discovery and diagnostic implementation.
Mishra’s conception of the healthcare company also extends beyond products and commercial growth. She sees industry as having a wider responsibility to cultivate technical knowledge, quality awareness, skilled talent and stronger industry-institution partnerships. GeneBio’s activities therefore encompass technical and regulatory services, contract research and manufacturing, as well as industrial training.
Capability building is particularly important in an industry where sophisticated technologies are only as effective as the people deploying and interpreting them. Stronger collaboration between research institutions and industry can similarly compress the distance between scientific expertise, manufacturing capability and regulatory understanding, creating a more connected route from discovery to healthcare application.
Technology transfer will remain central to this vision. The work with ICMR and other research-driven technologies reflects a broader objective: ensuring that promising scientific innovations do not remain confined to research settings but can be manufactured, scaled and ultimately reach the people who need them.
In that sense, her vision for GeneBio extends beyond building an Indian diagnostics organisation. It is about strengthening the entire chain of translation, so that innovation conceived in India can also be developed, manufactured, scaled and delivered in India.
Disclaimer: The above content is non-editorial, and TIL hereby disclaims any and all warranties, expressed or implied, relating to it, and does not guarantee, vouch for or necessarily endorse any of the content.
